CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		71 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
CASH FLOW FROM OPERATING ACTIVITIES
Net loss	$ (656,002)	$ (522,227)	$ (12,787,287)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	40,156	48,109	1,016,891
Technology impairment	0	0	690,000
Common stock issued for services	0	0	318,500
Stock options and warrants	16,019	19,356	3,029,773
(Increase) decrease in assets
Prepaid drug product for testing	99,000	132,000	(96,000)
Other current assets	(11,349)	(7,891)	(53,924)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	(38,828)	(69,536)	290,416
Net cash used in operating activities	(551,004)	(400,189)	(7,591,631)
CASH FLOW FROM INVESTING ACTIVITIES
Purchase of exclusive license - related party	0	(25,000)	(884,710)
Net cash used in investing activities	0	(25,000)	(884,710)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from convertible notes	0	0	435,000
Cash repayment of convertible notes	0	0	(15,000)
Net proceeds from sale of common stock	305,665	49,760	8,345,048
Net cash from financing activities	305,665	49,760	8,765,048
NET INCREASE (DECREASE) IN CASH	(245,339)	(375,429)	288,707
Cash, beginning of period	534,046	952,252	0
Cash, end of period	288,707	576,823	288,707
Cash paid for
Interest	0	0	445
Income taxes	0	0	0
Non-cash financing activities
Common stock issued upon conversion of convertible notes	0	0	420,000
Placement Agent
Non-cash financing activities
Common stock issued	0	0	591,566
MD Anderson for License
Non-cash financing activities
Common stock issued	0	0	2,354,167
LPC
Non-cash financing activities
Common stock issued	$ 0	$ 625	$ 210,755